Feature

Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

Preclinical results and AI integration support progress toward regulatory submission

Share

Hoth Therapeutics is leveraging AI technology to advance its investigational cancer therapy, HT-KIT, designed for rare cancers driven by KIT mutations. Utilizing the OpenAI API, the company integrates AI into its preclinical workflow for data analysis and regulatory documentation in preparation for Investigational New Drug (IND) filing. The orphan-designated therapy shows over 80% reduction in KIT expression in preclinical models and is moving towards phase I clinical trials, with no dose-limiting toxicities observed to date.

Original Source(s)

Hoth Applies AI in Development of Candidate for KIT-Driven Cancers

  • by Julia Cipriano

  • March 19, 2026

Related Content

Coalition urges Congress to boost CDC tobacco prevention funding

The ADA joined a coalition urging Congress to provide $310 million for tobacco prevention and cessation programs at the CDC.

Stockholm3 Test Cuts MRIs in Prostate Screening

Blood test algorithm reduces imaging demand in organized prostate cancer testing

  • March 19, 2026

  • 3 min
Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria

One in 10 patients who present to the emergency room (ER) with visible hematuria die within 3 months, new research from the United Kingdom has indicated. The WASHOUT study found that a scan administer...